Alibaba Group Holding Ltd (NYSE:BABA) reported higher-than-expected sales in Q3 and as its earnings were in line with the Street's view. Alibaba Group Holding Ltd (NYSE:BABA) was trading at $103.25, above the 52-week high in the range between $82.81 and $102.80. The Chinese e-commerce giant said non-GAAP earnings were $0.45 per diluted share, in line with the average estimate from analysts polled by Capital IQ. Sales rose were higher 53.7% at 16.8 billion renminbi ($2.74 billion), exceeding the $2.61 billion consensus estimate. Reported net income fell to 2.98 billion renminbi ($494 million) or 2.13 renminbi per diluted share from 4.88 billion renminbi or 1.24 renminbi per shareAchillion Pharmaceuticals Holding Ltd (NYSE:BABA) reported its Q3 loss widened from a year earlier. ACHN is trading in the upper half of the 52-week range between $2.41 and $13.80. The company which is developing antivirals for the treatment of chronic hepatitis C infection said its net loss widened to $15.67 million or $0.16 per share from $13.92 million or $0.14 the year earlier. Achillion Pharmaceuticals Holding Ltd (NYSE:BABA) said its hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015.It said that for the remainder of 2014, it expects to present results from a phase 2 study on its ACH-3102 in patients with treatment-naïve genotype 1 HCV at a presentation at The Liver Meeting in Boston starting Nov. 8. It also plans to present three posters on ACH-3422 at the same meeting, that will detail the preclinical profile of this Phase 1 direct-acting antiviral agent for HCV. Finally it will report phase 1 proof-of-concept results with ACH-3422 including safety following 14-day exposure in healthy volunteers and antiviral activity on treatment-naïve genotype 1 HCV patients. "We expect to report top-line results from our ongoing Phase 1 trial of ACH-3422 later this quarter and look forward to initiating a proprietary combination program evaluating ACH-3422, ACH-3102 and sovaprevir during 2015," chief medical officer David Apelian said in a statement.Clean Diesel Technologies, Inc. (NASDAQ:CDTI) shares rose 10% in early trading after the company said it has been granted the first two of a family of patents for a clean emissions exhaust technology that will reduce the cost of meeting more stringent clean air standards. The shares recently traded at $3.49 with a 52-week range of $1.33 - $7.39. The Spinel technology allows the replacement of costly platinum group and rare earth metals in catalytic converters. Clear Air said it believes the new technology will be "highly disruptive" to the platinum-based or rare-earth based device industry.Clean Diesel Technologies, Inc. (NASDAQ:CDTI) also said Tuesday that it's raising $3.8 million net through the sale of shares and warrants to a single investor. The unnamed investor will buy 1,553,571 shares of common stock for $2.80 per share, 168,571 of which are in the form of penny warrants that are being acquired for $2.79 per warrant. That's a discount of about 11% to Monday's closing price of $3.17. The investor will also receive regular warrants to acquire 388,393 additional shares at a price of $3.25 per share, $0.08 per share above the closing bid price on the date of pricing. The penny warrants will expire in six months; the regular warrants will expire five years from the date of issuance.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
